This acquisition will allow us to significantly strengthen the position of Röchling as a provider of sophisticated medical technology products and implement our growth strategy in the USA. Furthermore, we expect the acquisition to provide synergies with our other locations that are dealing with the issue of medical technology,” explained Professor Hanns-Peter Knaebel, CEO of the Röchling Group and responsible for the Medical division, giving the background to the acquisition.